Biotechnology

Edesa Biotech Secures $10 Million Credit Facility with Company Founder

October 12, 2023 12:15 PM

Revolving Line of Credit to Support Completion of Government-Funded ARDS Study TORONTO, ON / ACCESSWIRE / October 12, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA) ("Edesa", or the "Company"), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced it has entered into a binding commitment letter in respect of a $10 million revolving credit facility agreement with Dr. Par Nijhawan, MD, the...

Read more

Edesa Biotech to Receive Up To C$23 Million in Funding from Federal Government

October 12, 2023 12:10 PM

TORONTO, ON / ACCESSWIRE / October 12, 2023 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, has secured a commitment of up to C$23 million from the Government of Canada for a pivotal Phase 3 clinical study of the company's first-in-class therapeutic candidate. Edesa's experimental drug, called EB05 (paridiprubart), represents a new class of emerging therapies...

Read more

Bionoid Pharma Signs Exclusive License Agreement with Global Alerts Corp.

October 12, 2023 10:15 AM

Landmark Deal Signed in Global Mass Notification Market: Exclusive License Agreement for Rapid Deployment of World-Leading Early Warning Technology TORONTO, ON / ACCESSWIRE / October 12, 2023 / Bionoid Pharma, Inc. ("Bionoid") (OTC PINK:BINP) is pleased to announce an exclusive license agreement with Global Alerts Corp. ("Global Alerts"), a distinguished technology company dedicated to the development and worldwide deployment of state-of-the-art...

Read more

Lexaria Granted Two New Patents in Canada

October 12, 2023 9:10 AM

Lexaria now holds 37 granted patents world-wide Potential application in treating nicotine addiction KELOWNA, BC / ACCESSWIRE / October 12, 2023 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces it has been granted two new patents by the Canadian Intellectual Property Office ("CIPO"), increasing Lexaria's complete patent portfolio to 37 granted patents....

Read more

enVVeno Medical to Participate at the Virtual Investor Ask the CEO Conference

October 12, 2023 9:00 AM

Live moderated webcast with Robert Berman, Chief Executive Officer of enVVeno Medical on Wednesday, October 25th at 12:00 PM ET IRVINE, CA / ACCESSWIRE / October 12, 2023 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced that Robert Berman, Chief Executive Officer of enVVeno Medical, will participate at the Virtual Investor Ask...

Read more

M2MMA Announces 2024 Fight Schedule and Appoints CEO

October 12, 2023 8:30 AM

CAPE TOWN, SOUTH AFRICA / ACCESSWIRE / October 12, 2023 / Institute of Biomedical Research Corp. (OTC PINK:MRES), a vanguard entity at the forefront of nutraceutical biotechnology, specializing in alternative plant-based cannabinoids, medical psilocybin, and cutting-edge mental health therapeutic research driven by artificial intelligence (AI), is pleased to announce the following update with its M2MMA division: M2MMA, the latest division of...

Read more

Aronora Secures Investment From New York Blood Center

October 12, 2023 8:15 AM

Aronora is Revolutionizing Blood Clot Treatment with Groundbreaking Innovations PORTLAND, OR / ACCESSWIRE / October 12, 2023 / Aronora, Inc., a clinical-stage biotech poised to revolutionize blood clot treatment and prevention, today announced it has closed an investment from NYBC Ventures, a venture fund established by New York Blood Center. The funding will support team expansion, manufacturing, and regulatory activities as Aronora prepares...

Read more

Biovica Signs Agreement for DiviTum(R) TKa with World Re-known Cancer Clinic

October 12, 2023 3:00 AM

UPPSALA, SE / ACCESSWIRE / October 12, 2023 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) Biovica, active in cancer monitoring, today announces the signing of an agreement providing access to DiviTum TKa to appropriate patients treated at a leading cancer center in Florida. This center in Florida is part of a large and well renowned organization that serves all 50 states in US and international representation as well. In total,...

Read more

Adolore BioTherapeutics to Participate at the Virtual Investor Ask the CEO Conference

October 11, 2023 10:00 AM

Live moderated webcast with Roelof Rongen, Chief Executive Officer of Adolore BioTherapeutics on Wednesday, October 25th at 3:00 PM ET DELRAY BEACH, FL / ACCESSWIRE / October 11, 2023 / Adolore BioTherapeutics ("Adolore" or the "Company"), a company focused on developing breakthrough opioid-free gene therapy treatments for chronic pain, today announced that Roelof Rongen, CEO of Adolore, will participate at the Virtual Investor Ask the CEO...

Read more

Xenetic Biosciences, Inc. to Participate at the Virtual Investor Ask the CEO Conference

October 11, 2023 9:05 AM

Live moderated webcast with Jeffrey Eisenberg, Chief Executive Officer of Xenetic Biosciences on Tuesday, October 24th at 1:00 PM ET FRAMINGHAM, MA / ACCESSWIRE / October 11, 2023 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat oncology indications, today announced that Jeffrey Eisenberg, Chief Executive...

Read more

Edesa Biotech Announces One-for-Seven Reverse Share Split

October 10, 2023 9:00 AM

TORONTO, ON / ACCESSWIRE / October 10, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA) ("Edesa" or the "Company"), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today is announcing that it intends to effect a one-for-seven reverse share split of its common shares. The Company's common shares will continue to be traded on The Nasdaq Capital Market under the symbol "EDSA" and will begin trading on a...

Read more

BioInvent and Transgene: First patient treated in Part B of Phase 1 trial assessing the novel oncolytic virus BT-001 in combination with KEYTRUDA® (pembrolizumab)

October 10, 2023 2:00 AM

LUND, SE / ACCESSWIRE / October 10, 2023 / BioInvent International (STO:BINV) The Phase 1 Part B will evaluate the combination of BT-001 and pembrolizumab in solid tumors, including melanoma. LUND, SWEDEN / ACCESSWIRE / October 10, 2023 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy,...

Read more

CDBT - Terminates Consulting Agreement with Kenneth Maciora / Empire Relations Group

October 9, 2023 9:00 PM

ARUNDEL, AUSTRALIA / ACCESSWIRE / October 9, 2023 / China Dasheng Biotechnology Co. (OTC PINK:CDBT) advisors that the company has terminated the China Dasheng Biotechnology Co. Consulting Agreement with Kenneth Maciora, Empire Relations Group, Inc. and Empire Relations Holdings LLC. On July 10, 2023, CDBT entered the China Dasheng Biotechnology Co. Consulting Agreement which had a 3-month period expiring on October 10, 2023, with an upfront fee...

Read more

GENZEVA and RYLTI Partner to Develop a Groundbreaking Application to More Clearly Understand the Molecular Mechanisms of Disease

October 6, 2023 1:15 PM

A joint study applying Genzeva's new breakthrough genomic research process reveals remarkable discovery by uncovering hidden "dark" data. ROCKVILLE, MD / ACCESSWIRE / October 6, 2023 / Genzeva, a leading molecular genetic laboratory that performs whole genome and clinical exome sequencing for clinical diagnostics and research, has partnered with tech innovator RYLTI to develop an innovative groundbreaking application of AI Knowledge Engineering...

Read more

enVVeno Medical Achieves Full Enrollment for VenoValve U.S. Pivotal Trial

October 6, 2023 8:57 AM

- 18 VenoValve patients enrolled over the final two months of the study - Surge in VenoValve demand exceeded the enrollment limit - Topline safety and efficacy readout and PMA eligibility now expected to occur in Q4 2023, Q2 2024, and Q3 2024, respectively IRVINE, CA / ACCESSWIRE / October 6, 2023 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease,...

Read more

enVVeno Medical Announces New Expedited Development Plan for the enVVe(R) Transcatheter Based Replacement Venous Valve

October 6, 2023 8:56 AM

- enVVe development cycle to be reduced by 6 months - Application for enVVe pivotal trial now expected to be ready by end of 2024 IRVINE, CA / ACCESSWIRE / October 6, 2023 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced a plan to expedite the development of enVVe®, its transcatheter based replacement venous valve. The new plan...

Read more

enVVeno Medical Announces Private Placement of $28 Million

October 6, 2023 8:55 AM

Up to an additional $34 million of capital may become available from milestone-driven warrants in Q2, 2024 upon the release of initial topline efficacy data from the VenoValve pivotal trial Up to an additional $41 million of capital may become available from milestone-driven warrants upon expected FDA pre-market approval of the VenoValve IRVINE, CA / ACCESSWIRE / October 6, 2023 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the...

Read more

Auxilius Completes SOC 1 Type 2 Certification

October 5, 2023 9:00 AM

Rigorous Audit Validates Auxilius as a Trusted Clinical Trial Financial Management Platform, a Key Element of Compliance and Assurance of Controls for the Highly Regulated Life Sciences Industry MANHATTAN, NY / ACCESSWIRE / October 5, 2023 / Auxilius, the most widely used platform for clinical trial financial management, announced that it has successfully completed the Service Organization Control (SOC) 1 Type 2 audit. Conducted by Geels Norton...

Read more

Gerresheimer AG: Gerresheimer on Track to Another Strong Financial Year

October 5, 2023 1:20 AM

Organic revenue growth of 12.6% in the first nine months of the financial year 2023 Adjusted EBITDA up organically by 20.6% Order intake at record high: new orders for syringes and pens for GLP-1 drugs Guidance for full-year 2023 confirmed DUESSELDORF, GERMANY / ACCESSWIRE / October 5, 2023 / Gerresheimer, innovative provider of systems and solutions and global partner for the pharma, biotech, and cosmetics industries, made progress toward...

Read more

Petros Pharmaceuticals Announces Positive Outcomes in Label Comprehension Study for Potential OTC STENDRA Label

October 4, 2023 9:00 AM

Company well positioned to continue collaboration with FDA toward pursuit of OTC pathway for STENDRA NEW YORK, NY / ACCESSWIRE / October 4, 2023 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI), a company focused on expanding consumer access to medication through over the counter (OTC) nonprescription pathways, announces completion of a pivotal label comprehension study (LCS). Using FDA guidance provided to the company in 2022, the LCS is expected...

Read more